2018 MEETINGS
I ERIC INTERNATIONAL MEETING: NEW FRONTIERS IN CLL RESEARCH
25-27 OCTOBER 2018 (BARCELONA, SPAIN)
ERIC WORKSHOP ON IG ANALYSIS
04 JULY 2018 (TEL-AVIV, ISRAEL)
45th GENERAL ASSEMBLY OF ERIC MEMBERS AT EHA 2018
14 JUNE 2018 (STOCKHOLM, SWEDEN)
- Agenda
- Welcome and introduction (Paolo Ghia)
- Final analysis of GIMEMA-ERIC UK Study on BR including indirect comparison with ibrutinib as first salvage treatment / Preliminary data on the efficacy of BR in first line (Antonio Cuneo)
- Large-scale gene mutation analysis (Lesley Ann Sutton)
- Prevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib (Lydia Scarfo)
- Update on Round 3 of IGHV Certification (Kostas Stamatopoulos)
- TP53 Certification – Summary of Rounds 1-5 and update on Round 6 – S. Pospisilova / S. Pavlova
- ERIC International Meeting – Barcelona (Paolo Ghia)
- ERIC Educational Workshops – Belgrade and Russia (Kostas Stamatopoulos)
INTERNATIONAL WORKSHOP BIOMARKER-GUIDED MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
13 APRIL 2018 (MOSCOW, RUSSIA)
- Agenda
- Biomarkers – what is their role in the management of patients with CLL? (Kostas Stamatopoulos)
- Banding analysis (Panagiotis Baliakas)
- Array CGH (Anne-Marie van der Kevie-Kersemaekers)
- Beyond TP53: novel recurrent gene mutations (Lesley Ann Sutton)
- Interactive case session on TP53 aberrations (Panagiotis Baliakas / Jon Strefford)
- Methodological considerations (Andreas Agathangelidis)
- Interactive case study (Kostas Stamatopoulos)
- Meet the expert – Tailoring treatments to individual patient profiles in CLL (Richard Rosenquist)
INTERNATIONAL WORKSHOP BIOMARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE ART OF SYNTHESIS
16-17 MARCH 2018 (BELGRADE, SERBIA)
- Agenda
- Current considerations to clinical decision making in CLL (Kostas Stamatopoulos)
- Interactive case session (Michael Doubek )
- Array CGH (Gian Matteo Rigolin)
- Interactive case session (Kostas Stamatopoulos / Michael Doubek)
- Banding Analysis (Panagiotis Baliakas)
- Overview (Sarka Pospisilova)
- Methodological considerations (Sarka Pavlova )
- Interactive case study (Fred Davi / Jon Strefford )
- Methodological considerations (Anton Langerak)
- Interactive case session (Andreas Agathangelidis / Frederic Davi)
- Overview (Anastasia Hadzidimitriou)
- Beyond TP53: novel recurrent gene mutations (Lesley-Ann Sutton)
- NGS immunogenetics (Anton Langerak)
- The ERIC TP53 Network (Sarka Pospisilova)
- The ERIC IG Network (Anastasia Hadzidimitriou)
- Concluding remarks: What does the future hold for CLL patients (Kostas Stamatopoulos)